Investigations of renal function using the level of neutrophil gelatinase-associated lipocalin associated with single-dose of cisplatin during chemotherapy.

backgroundNeutrophil gelatinase-associated lipocalin (NGAL) is known as a primary indicator of acute and chronic renal and can be effective in chronic kidney injury (CKI) with kidney tumors cisplatin (CP) chemotherapy. The aim of this study was to evaluate serum and urinary biomarker including NGAL (sNGAL and uNGAL) in canine with solid renal tumors who suffered from cisplatin after short and long-term chemotherapy.

methodsIn this study, in treatment and control groups, canine (n = 10 and n = 5) were administered cisplatin at 1.2 mg/kg/day (i.v.) for five consecutive days with CKI and without CKI, respectively. Serum and urine NGAL levels (ng/mL) were evaluated at 0, 1, 5, 9, 13, 17, 21, 25 and 29 days after drug injection versus baseline in treated and control groups.

resultsCanine in treatment group had shown symptoms of toxicity of cisplatin. The results indicated the higher concentrations of serum, sNGAL and uNGAL (P = 0.024; P = 0.011) compared with control group (P = 0.701, P = 0.612), (Table 2, Figs. 1 and 2). Indeed, our results showed that canine with CKI were associated with higher levels of sNGAL and uNGAL compared with control group without CKI. Moreover, the highest level of uNGAL was seen in comparison with sNGAL, after a high dose (1.2 mg/kg) administration of CP.

conclusionOur data suggested that U-NGAL may be useful for monitoring of renal injury in CKI patients that exposed with cisplatin. Furthermore, a primary elevate in urinary NGAL expulsion may help in identifying cases at danger of cisplatin-induced CKI that might profit from innovative remedies to prevent cisplatin nephrotoxicity.